stockportfolio.pro
Stocks / RCUS vs TARS
RCUS vs TARS
Arcus Biosciences, Inc. and Tarsus Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Arcus Biosciences, Inc. (RCUS) | Tarsus Pharmaceuticals, Inc. (TARS) | |
|---|---|---|
| Market cap | $2.8B | $2.7B |
| Revenue (latest FY) | $247.00M | $451.36M |
| Net income (latest FY) | $-353.00M | $-66.42M |
| Revenue growth (5y CAGR) | 25.9% | — |
| Net margin | -142.9% | -14.7% |
| Return on equity | -55.9% | -19.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open RCUS — free Open TARS — freeFrequently asked questions
Which is bigger, RCUS or TARS?
Arcus Biosciences, Inc. is larger by market capitalization — $2.8B versus $2.7B.
Which grows faster, RCUS or TARS?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.